Cargando…
Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis
Purpose: Ranolazine is a novel anti-angina treatment approved in the United States for chronic stable angina. Ranolazine pharmacokinetics have not been studied previously in patients who receive maintenance hemodialysis. This study describes the pharmacokinetics of ranolazine and three major metabol...
Autores principales: | Scoville, Bridget A., Segal, Jonathan H., Salama, Noha N., Heung, Michael, Bleske, Barry E., Eyler, Rachel F., Mueller, Bruce A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442103/ https://www.ncbi.nlm.nih.gov/pubmed/30909832 http://dx.doi.org/10.1080/0886022X.2019.1585371 |
Ejemplares similares
-
Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats
por: Mashayekhi-sardoo, Habibeh, et al.
Publicado: (2022) -
Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation
por: Lewis, Susan J., et al.
Publicado: (2023) -
Update on ranolazine in the management of angina
por: Codolosa, J Nicolás, et al.
Publicado: (2014) -
Ranolazine for Angina in Hypertrophic Cardiomyopathy
por: Amin, Akhtar, et al.
Publicado: (2018) -
Ranolazine: A Contemporary Review
por: Rayner‐Hartley, Erin, et al.
Publicado: (2016)